🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

urothelial cancer highlight #ESMO24 New ADC data (1st line DV/pembo, EGFR/HER3),TAR200 (pretzel) in MIBC (SUNRISE4), EV/pembro biomarkers (EV302), adjuvant (TOMBOLA) and neoadjuvant (VOLGA) ctDNA, updates on adjuvant pembro (AMBASSADOR), neoadjuvant chemo +/- durvalumab (NIAGRA)

Disitimab vedotin + Pembrolizumab in 1L treatment for mUC presented by Matt Galsky. Thrilled to have participated in this trial University Hospitals Case Comp Cancer Ctr 🎯 HER2 is important target even in HER2 low patient 🏆 75.0% ORR, 35% CR ➡️ DV + P vs DV randomization ongoing

Disitamab plus pembrolizumab demonstrates encouraging activity👉 in treatment naive HER2 expressing advanced #bladdercancer 👇Excellent talk by Matt Galsky ESMO - Eur. Oncology #ESMO24 UroToday.com OncoAlert Tom Powles

NIAGARA is the first randomized trial to demonstrate significant OS difference in the NIBC perioperative trest. #ESMO24 Tom Powles did it again!!! Another practice changing trial in the back OncoAlert ESMO - Eur. Oncology

Enrique Grande Tom Powles OncoAlert ESMO - Eur. Oncology Excellent data!! And now, let’s go for bladder preserving approaches!!!

Kann ich mich nur anschließen tolle Arbeit !!!

Congratulations to Gamal Wakileh for Winning the Research and Innovation Prize for Urological Oncology at #DGU24 👏🎉 DGU European Association of Urology (EAU) UroToday.com @UrooncologyUKD Uniklinik Ulm ehoonline.biomedcentral.com/articles/10.11…

CUT-less Trial 🫶🏻 Sapienza Università di Roma Sapienza Urology Stanford Urology EAU YAU Urothelial Carcinoma Valeria Panebianco Martina Pecoraro Tanja Hüsch,MD Benjamin Pradere 🇮🇹

An international multi-centre RCT on ERBT vs conventional TURBT: First results of the EBRUC II trial doi.org/10.1111/bju.16…

Great talk by Dr. Axel Bex! Mirrors of Medicine OncoAlert #RENALC24

Fantastic talks on practical surgical questions on DAY 2 of #BLADDR24 - Practical aspects of intravesical instillation by Fred Witjes - The optimal TURBT by Ben-Max de Ruiter - The impact of RC on sexual function/experience by Pignot Géraldine Moderation: Cédric Lebâcle OncoAlert

JUST IN: U.S. FDA expands Lu-PSMA metastatic castration-resistant prostate cancer indication: now in Taxane-Naive population. Approval based on PSMAfore trial open Dana-Farber Lank Center for Genitourinary Oncology -rPFS 9.3 vs. 5.6mos (HR: 0.41) -OS HR 0.91 Through ASCO FDA alerts.

The FDA approved perioperative duvalumab with neoadjuvant chemo for muscle invasive bladder cancer today. It’s the only perioperative immune therapy trial with significant OS (0.75). Surgical safety was maintained. NCCN approval recently too #GUtrends25 fda.gov/drugs/resource…

CD46 is a novel and intriguing new target in prostate cancer Journal of Clinical Oncology ASCO

TAR-200 in BCG-unresponsive NMIBC #AUA25 •82% CR rate at anytime •53% ≥12-mo durability CR •86.6% cystectomy-free at 12 mo If you compare to other available tx➡️➡️At 12 mo duration ‼️TAR-200 53% ≥12-mo DOR vs Adstiladrin 46%, Anktiva+BCG 58%

The positive CREST study (BCG + Sasanlimab) in NMIBC was published today (Neal Shore et al). #ASCO25

🤩Privileged to be co-author in this paper on the CREST trial published at Nature Medicine with Tom Powles Matt Galsky Joan Palou Redorta Evanguelos Xylinas Alberto Briganti among others 🙌🏼Thrilled to be part of an eventual paradigm shift in #NMIBC after 50 years 👣This is only the

Our team is in Sevilla for #UROonco25 📩 #NMIBC Deintensify LG Biomarkers to ⬇️ cystoscopy in HG #MIBC ctDNA is the future #UTUC Tailored patient care Go for kidney-sparing treatment European Association of Urology (EAU) EAU Edu Platform UROONCO EAU Young Academics

Interdisciplinary #GUCancerForum 2025: The role of ctDNA in selecting adjuvant therapy post-cystectomy. Presentation by Gennady Bratslavsky Upstate Medical University. Written coverage by Zach Klaassen Georgia Cancer Center > bit.ly/3ZGbYUc